FDA staff questions Sanofi bird flu vaccine
WASHINGTON (Reuters) - Data on Sanofi-Aventis's (SNY.N) (SASY.PA) experimental bird flu vaccine shows higher doses worked better, but it is unclear whether those results prove the product's effectiveness, U.S. regulatory staff said in documents released on Monday.
Food and Drug Administration staff also said studies of the vaccine, which targets the potentially pandemic H5N1 strain of the influenza virus, showed "no significant safety signals."
- U.S. military strike in Somalia targeted al Shabaab leader
- Marilyn Monroe sex film to be kept private |
- Islamic State issues video of beheading of U.S. hostage |
- Actress Jennifer Lawrence contacts authorities after nude photos hacked
- Ukraine accuses Russia of 'undisguised aggression' as rebels advance |